series-c-plus
Stage
1
Investors
About
Skyhawk Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics that modify RNA expression. Its pipeline includes programs across neurodegenerative, neuromuscular, oncology and fibrotic diseases.
Explore Skyhawk Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.